arcadia biosciences glp-1 receptor agonist weight management diabetes treatments Harnessing Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon Weight Reduction with GLP-1 Agonists

Adylxin FDA Safety Label Change Bydureon BCISE extended-release (exenatide synthetic) subcutaneous weekly injection FDA Approval Year: 2017 Bydureon Extended Release Safety Label Change Byetta (exenatide synthetic) subcutaneous twice-daily injection FDA Approval Year: 2005 Byetta FDA Safety Label Change Mounjaro (tirzepatide) subcutaneous weekly injection FDA Approval Year: 2022 The Gastrointestinal Adverse Reaction section added that a small number of patients have reported the experience of dysgeusia (altered sense of taste)

adults and driving rising health costs and economic burdens

For instance, medications like Semaglutide GLP-1 (Ozempic) may require daily injections, typically taken at the same time each day

Annals of internal medicine , 177 (8), 10161027

Lancet 14:110 Son JW, Kim S (2020) Comprehensive review of current and upcoming anti-obesity drugs